Life Science Leader Blogs
-
The Leadership Meeting – Where Leaders Go To Learn
1/21/2020
Rob Wright provides a high-level overview of The Leadership Meeting, a pre-JPM conference with content specifically curated for professional development of c-level life science leaders.
-
Brightspot: How A Biopharma VC Makes A Difference For Orphans
12/17/2019
Ed Torres, managing partner at Lilly Ventures, shares how he and his wife got involved in making a difference for U.S. orphans.
-
The CNS Summit — A Caring Community Of Collaborative Solution Finders
11/26/2019
Chief editor Rob Wright explains what differentiates the CNS Summit from other biopharmaceutical industry conferences.
-
Making A Difference For Veterans: A Biopharma Bright Spot
11/18/2019
The little known story of an immigrant couple making a $15 million difference for U.S. veterans.
-
Negative Perceptions Of Biopharma — Let’s Get The Ugly On The Table
11/1/2019
A Life Science Leader reader shares their thoughts on why the biopharmaceutical industry’s reputation is so dismal, but also proposes solutions for how to repair it.
-
Want To Start Fixing Biopharma’s Reputation? Let’s Start By Sharing More Biopharma Brightspots
10/10/2019
With the biopharmaceutical industry’s reputation at an all-time low, Life Science Leader’s Rob Wright looks to share little-known stories of the good being done by employees of biopharma. This first installment involves Antoine Yver, M.D., EVP and global head of R&D at Daiichi Sankyo, who helped to cofound a 501(c)3 nonprofit restaurant, The Blue Bears Special Meals.
-
Have We Seen The End Of Competitive Advantage?
9/20/2019
Thinker50 member and Columbia Business School Professor Rita Gunther McGrath, Ph.D., believes we have seen the end of sustainable competitive advantage, but has some solutions for businesses open to building strategies around transient competitive advantage.
-
Biopharma’s Reputation — Out Of The Frying Pan And Into The Fire
9/10/2019
Chief Editor Rob Wright discusses the implications of the recent Gallup poll indicating pharma presently being the most poorly regarded of all industries in the eyes of Americans.
-
The Opioid Addiction Crisis — A Historical View From The Front Lines
9/3/2019
Chief Editor Rob Wright saw glimpses into the impending opioid crisis back when he was working as a pharma sales rep in the pain management space.
-
Is It Time To Throw In The Towel On Biosimilars In The U.S.?
8/23/2019
Rob Wright takes issue with Peter Bach, M.D., and Mark Trusheim’s recommendation that the U.S. would be better served by abandoning continued biosimilar drug development.